The latest analyst rating for Vertex Pharmaceuticals (NASDAQ:VRTX) was provided by RBC Capital, and Vertex Pharmaceuticals maintained their sector perform rating. The last upgrade for Vertex ...

The stock is up 8.6% since reporting and currently trades at $510.02. Is now the time to buy Vertex Pharmaceuticals? Access our full analysis of the earnings results here, it’s free. Pioneering ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Explore Vertex Pharmaceuticals stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for VRTX. CrowdStrike, Robinhood, Palo Alto Networks And A Health Care Stock ...

Zimislecel (VX-880) pivotal trial on track to complete enrollment and dosing in H1 2025; Vertex expects to submit marketing applications to global regulators in 2026 - Vertex has completed ...